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Summary: Patients with hypopituitarism display impaired quality of life and excess morbidity 
and mortality, despite apparently optimal pituitary hormone replacement. Oxytocin is a 
neuropeptide synthesised in the anterior hypothalamus which plays an important role in controlling 
social and emotional behaviour, body weight and metabolism. Recent studies have suggested that 
a deficiency of oxytocin may be evident in patients with hypopituitarism and craniopharyngioma, 
and that this may be associated with deficits in cognitive empathy. Preliminary data hint at 
potential benefits of oxytocin therapy in improving these deficits and the accompanying metabolic 
disturbances that are common in these conditions. However, several challenges remain, including 
an incomplete understanding of the regulation and mechanisms of action of oxytocin, difficulties 
in accurately measuring oxytocin levels and in establishing a diagnosis of oxytocin deficiency, and 
a need to determine both the optimal mode of administration for oxytocin therapy and an 
acceptable safety profile with long-term use. This review considers the data linking oxytocin to 
the neuropsychological and metabolic disturbances evident in patients with craniopharyngioma 
and hypopituitarism, and describes the challenges that need to be overcome before replacement 
therapy can be considered as a therapeutic option in clinical practice.  
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Synthesis and Secretion 
First discovered by Sir Henry Dale in 1906 and sequenced by du Vigneaud and colleagues in 1954, 
oxytocin (OT) is a nonapeptide hormone synthesised principally by magnocellular neurons located 
in the hypothalamic paraventricular and supraoptic nuclei (figure 1). OT is initially synthesised as 
an inactive precursor protein containing its carrier protein neurophysin I, which undergoes 
progressive hydrolysis to release active OT. A single axon arising from each magnocellular neuron 
projects to the posterior pituitary gland where OT release is triggered by exocytosis from 
neurosecretory vesicles in response to depolarisation (1). The blood-brain barrier largely prevents 
OT molecules released in this manner from re-entering the central nervous system (2). 
Nevertheless, endogenous brain OT concentrations are significantly higher than in the periphery 
(1) and do not appear to correlate with plasma levels (3). OT is also released to other brain regions 
via dendritic diffusion as well as via axonal connections from parvocellular neurons to regions 
such as the nucleus accumbens, nucleus tractus solitarius, arcuate nucleus and spinal cord (figure 
1). Furthermore, OT is synthesised at other sites, including the retina, pancreas, thymus, adrenal 
medulla, placenta and corpus luteum, although the physiological relevance of production at these 
sites is unclear. 
 
Early studies suggested that circulating plasma OT concentrations are relatively stable in the basal 
state (4) but recent observations using deconvolution analysis have confirmed that a pulsatile 
pattern of OT secretion exists in men at rest and that OT concentrations correlate with indices of 
socio-emotional functioning (5). In keeping with the progressive rise in OT levels during 
pregnancy, OT concentrations are stimulated in response to oestrogen administration (6, 7); 
however, they may not vary significantly according to phase of the menstrual cycle (6, 7). Some 
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(4, 8), but not all (9), studies report a diurnal variation in secretion, with concentrations at their 
lowest in the afternoon and evening, and rising steeply after midnight (4). It is unclear if ageing 
has an effect on secretion: although one study showed no effect of age on either the pattern of 
release or absolute OT concentrations (4), only a small number of subjects were included and 
further studies are needed. In women, physiological stimuli such as breastfeeding and labour 
induce a pulsatile release of OT into the peripheral circulation whereas in men, peripheral OT 
concentrations have been shown to rise during sexual arousal (10).  
Peripherally administered OT has a very short half-life in human plasma (2-8 minutes) (11) and 
displays poor permeability across the blood-brain barrier, with <1% of peripherally-administered 
OT appearing in the cerebrospinal fluid (CSF)  (2, 12). These pharmacokinetic properties present 
a challenge when considering its therapeutic potential as a neuroactive drug. OT exerts its effects 
through binding to the G protein-coupled OT receptor. Although only one canonical receptor for 
OT is thought to exist in mammals, arginine-vasopressin (AVP), which shares seven of nine amino 
acids, is thought to have three: the V1a, V1b and V2 receptors. These evolutionarily ancient 
receptors exhibit a high degree of structural homology, hence it is not surprising that considerable 
cross-talk between OT and AVP and their receptors can occur (13). This has implications not only 
for our understanding of the roles of these peptides in a variety of physiological processes but also 
for drug design with respect to receptor selectivity.  
 
Physiological effects  
OT has a well-established role in the regulation of labour, in keeping with its derivation from the 
Greek for ‘quick birth’. It stimulates cervical ripening and dilatation, is uterotonic, and facilitates 
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uterine contraction and clotting in the postpartum period.  OT also stimulates breast myoepithelial 
cells to help initiate the let-down reflex in lactation (figure 2).  
More recently, its role in the regulation of a number of other physiological processes has become 
appreciated, notably in relation to food intake and metabolism (14). Knockout mice deficient in 
either OT or the OT receptor are obese and glucose intolerant (15, 16), whilst OT administration 
reduces food intake, increases energy expenditure and improves glucose homeostasis (17-19). The 
effects on food intake are rapid and sustained (17, 18), with obese rats appearing to be more 
sensitive to the effects of OT on weight loss than lean animals (20). In humans, studies have shown 
that peripheral OT levels are elevated in obesity (21) and the metabolic syndrome (22), and 
correlate with BMI and fat mass (21, 22). Conversely, OT concentrations may be lowered in the 
presence of overt diabetes (23-25).  Acutely, intranasal OT administration reduces caloric intake 
(26, 27) with a preferential reduction in fat consumption (26); as in animals, these effects are more 
pronounced in obesity (27). These actions may be mediated at least in part by modification of 
hedonic as well as homeostatic pathways (14, 17, 28). Single dose experiments have also shown 
an increase in fat oxidation (26), and beneficial effects on glucose homeostasis and insulin 
sensitivity (26-29). Conversely, the benefits seen in animal models with respect to increased 
energy expenditure have not yet been confirmed in humans (26, 28). An important caveat is that 
the OT dose used in these studies may be considered supra-physiological (24 IU), exceeding both 
the estimated OT store in the posterior pituitary (14 IU) and the intravenous doses employed in 
labour (1-30 mIU/min). At these doses, some of the effects of OT may be mediated via actions at 
AVP receptors (30). Furthermore, studies to date have been largely limited to men, hence it is 
unclear whether these metabolic benefits are also apparent in women. In contrast to acute 
administration, only a few studies have examined the effects of sustained OT administration on 
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body weight and metabolic outcomes, although a number of clinical trials are ongoing. In a 
randomised, placebo-controlled study of intranasal OT (24 IU four times daily) in subjects with 
overweight/obesity, OT reduced body weight by a mean of 9kg after 8 weeks, albeit that only 9 
participants received active treatment (19). Conversely, no effects on weight were seen in two 
randomised, placebo-controlled trials of intransal OT in Prader-Willi syndrome (31, 32), although 
the total daily OT exposure was lower in these studies than in Zhang et al (19).         
Oxytocin receptors are expressed in the adrenal and anterior pituitary glands, hence it is not 
surprising that OT administration has an effect on the hypothalamic-pituitary-adrenal (HPA) axis. 
Studies have shown consistently that OT, whether administered intravenously or intranasally, 
reduces ACTH and cortisol secretion under both basal and stress conditions (33-35). Intravenous 
OT has also been shown to block corticotrophin-induced ACTH release (36), although no reports 
of hypoadrenalism have emerged to date. In animals, OT has been shown to modulate sodium 
balance but recent data in humans showed no influence of dietary sodium intake on circulating OT 
levels (37). Nevertheless, given its ability to bind to vasopressin receptors including the V2 
subtype, hyponatraemia may develop in response to treatment, at least in high doses such as those 
used in labour (38).   
 
Psychological Effects 
Early studies in the 1990s demonstrated profound effects of OT on sexual and maternal behaviour 
in animals, since replicated in human studies which confirm an important role of OT in normal 
parenting (39). OT is now known to exert a wide range of effects on human social and emotional 
behaviour (figure 2), from influencing the way in which individuals respond to social exclusion 
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(40, 41), to moral dilemmas (42) and how they allocate resources (43). Moreover, OT regulates 
the way in which individuals process emotional information (44) and, in turn, facilitates the 
identification of emotions (45); as such OT may be implicated in many mental health disorders. 
Altered OT concentrations or responses are evident in patients with postnatal depression (46), 
schizophrenia (47), autism spectrum disorder (ASD) (48) and attention-deficit hyperactivity 
disorder (49).  
Given OT’s pivotal role in adaptive social behaviour, studies have investigated the potential 
therapeutic role of OT administration in improving characteristic behavioural symptoms 
associated with these disorders. For example, Tauber et al (50) found that infants with Prader-
Willi Syndrome who received intranasal OT showed improved sucking, increased acylated ghrelin 
production and improved parent-infant interaction. To date, the disorder that has received the most 
attention with regard to the therapeutic potential of OT is ASD, with a systematic review finding 
significant benefits with respect to emotion recognition and eye-gaze (48). While clinical trials 
into the effects of OT in individuals with ASD are ongoing, larger and longer-term studies are 
needed to confirm these findings and those in other mental health disorders.  
 
Morbidity, mortality and quality of life in hypopituitarism: an unmet need 
Hypopituitarism, referring to reduced secretion of pituitary hormones, affects roughly 45 people 
per 100,000 of the general population. Pituitary adenomas, extrasellar tumours and treatments for 
these tumours (surgery, radiotherapy) account for the majority of cases in adults, although 
infective, inflammatory, infiltrative, traumatic, vascular and congenital disease may also occur. 
This diverse range of aetiologies contributes to differences in morbidity and treatment outcomes. 
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Notably, hypothalamic insult, whether arising directly from tumours (such as craniopharyngioma) 
or treatments for such tumours (especially surgery), is a major cause of morbidity (51, 52), not 
least due to obesity and its metabolic sequelae, arising as a result of disruption to appetite-
regulating centres. Although the introduction of glucocorticoid, thyroid, sex steroid and growth 
hormone replacement therapy has transformed outcomes in hypopituitarism, a number of studies 
have shown that the mortality and morbidity experience of patients still does not reach population 
norms. Meta-analyses have consistently demonstrated an excess mortality in hypopituitarism 
despite apparent optimal replacement therapy (53, 54), driven largely by deaths related to vascular 
disease. The risks of premature death appear greater in young-onset disease and in women (54). 
Of note, the standardised mortality ratio in patients with craniopharyngioma is particularly high 
(52, 54, 55).  
Several studies have demonstrated impaired quality of life (QOL) in patients with hypopituitarism, 
whether measured by generic or disease-specific tools (56, 57). QOL is particularly impaired in 
craniopharyngioma (58, 59), with the most common domains affected including emotional and 
social functioning (58, 59). Additional treatments are therefore needed to address this burden and 
to improve patient experience.      
 
Oxytocin in hypopituitarism  
In light of the impaired QOL, neuropsychological deficits and obesity frequently evident in 
patients with craniopharyngioma, and OT’s synthesis in the hypothalamus, studies have begun to 
address whether OT deficiency is present in hypopituitarism, and if so whether this is accompanied 
by psychological deficits that might be amenable to therapeutic intervention (table 1). A 2016 case 
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report highlighted an improvement in pro-social behaviour in response to nasal OT in a boy 
following surgical treatment of a craniopharygioma (60). Daubenbüchel and colleagues 
subsequently compared salivary OT concentrations in 34 patients in the German Childhood 
Craniopharyngioma Registry and 73 healthy volunteers (61), finding no difference in OT levels 
between groups. They speculated that this might reflect either preserved hypothalamic function or 
compensatory secretion by other neuronal pathways, such as the medial preoptic area, 
striaterminalis and lateral amygdala (62). Dendritic as opposed to axonal OT release might also 
account for these findings. However, they did find lower fasting OT concentrations in patients 
with post-surgical lesions to the anterior hypothalamus (where the paraventricular and supraoptic 
nuclei are located), albeit that only 6 patients fell into this category. Counter to expectation, OT 
levels were not lowered in patients with more extensive hypothalamic involvement (anterior and 
posterior regions), for reasons that aren’t immediately clear. Gebert and colleagues subsequently 
compared salivary OT levels, at baseline and following an exercise stimulus, in 26 adult 
craniopharyngioma patients and 26 age/sex-matched controls (63). OT concentrations as a whole 
were not different between groups, but were reduced in patients with hypothalamic damage as 
assessed by MRI. Exercise-induced rises in OT were also blunted in the patient group. Of note, 
they did not find a relationship between the presence of diabetes insipidus and OT concentrations, 
indicating that diabetes insipidus cannot be used reliably as a proxy for OT deficiency, with the 
caveat that desmopressin may cross-react in some immunoassays. Counter to expectation, higher 
baseline OT concentrations were associated with higher trait anxiety, whereas blunted OT 
secretion in response to exercise was linked with higher state anxiety. No association was observed 
with measures of empathy. Our own study examined salivary OT concentrations in fifty-five 
participants, comprising 20 patients with central diabetes insipidus and anterior hypopituitarism, 
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15 patients with anterior hypopituitarism alone (clinical controls) and 20 healthy volunteers (64). 
Groups were matched for age and gender. To our surprise, hypopituitarism was associated with 
reduced OT concentrations irrespective of the presence or absence of diabetes insipidus, 
potentially indicating an influence of anterior pituitary hormones on OT secretion. Patients with 
hypopituitarism also performed worse on two empathy tasks, with regression analyses revealing 
that OT concentrations significantly predicted ability to correctly identify facial expression. A 
specific deficit in empathy was also supported by analysis of self-report measures, with 
hypopituitary patients demonstrating significantly lower trait empathy compared to healthy 
controls. In a recent small pilot study in 10 childhood craniopharyngioma patients, Hoffman and 
colleagues demonstrated an improvement in emotion recognition in response to a single intransal 
dose (24 IU) of OT (65). Collectively, these data suggest that patients with hypopituitarism may 
present with a deficiency in OT associated with reduced cognitive empathy, and that this might be 
amenable to treatment with OT replacement. 
In contrast to neuropsychological studies, observations on the effects of OT on body weight in 
patients with hypopituitarism are sparse, and limited to a single case report in which a 13 year old 
boy with hypothalamic obesity post-surgical resection of a craniopharyngioma was treated with 
OT (66). MRI had shown evidence of injury to the anterior hypothalamus. OT was administered 
intranasally for 10 weeks at an eventual dose of 6 IU daily. In addition to weight loss of 4.4 kg 
during this time, qualitative improvements with respect to satiety, reduced urgency to eat and 
decreased food preoccupation were noted. Subsequent addition of the opiate antagonist naltrexone 
in combination with OT resulted in continued profound reduction in weight and hyperphagia. 
Although testosterone therapy to induce puberty may have contributed in part to these 
improvements, it should be noted that this was not introduced until 4 months after OT 
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commencement. OT treatment was well-tolerated with no reported adverse effects. Finally, several 
patient reports on blog and social media sites describe positive benefits in response to OT therapy 
used off label. Whilst such anecdotes should be treated with some caution, they should at least 
serve as a reminder that the demand for new treatments to improve quality of life is high in the 
hypopituitary community.  
 
Diagnostic challenges 
Whilst these observations of a potential neuropsychological and metabolic benefit of OT in 
hypopituitarism are encouraging, a number of challenges need to be addressed before OT can be 
considered for adoption into clinical practice. Firstly, reliable measurement of plasma OT 
concentration is not straightforward (67). Falsely elevated OT levels are often observed with 
modern radioimmunoassays due to interference from other immunoreactive products (68), a 
problem common also to enzyme-linked immunosorbent assays (ELISAs). Sample extraction (by 
solid phase or solvent) is a procedure designed to eliminate the effect of potentially interfering 
products, reduce matrix effects and concentrate the analyte from the sample before analysis. Whilst 
extraction removes some of these interfering substances, ELISAs may still detect OT degradation 
products, whose biological activity is unknown. Moreover, the need for an extraction step is itself 
open to question since it eliminates protein-bound OT with the potential to falsely lower OT 
concentrations (69). Mass spectrometry-based methods may offer an important advance as they 
offer high selectivity and sensitivity. OT concentrations measured in this manner are significantly 
higher than reported for established techniques since total OT is measured, which is largely 
protein-bound (69). Salivary OT measurement is also problematic and requires further validation, 
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not least because of weak correlation with immunoassay measures of unextracted OT in plasma 
(67); the biological relevance of OT measured at this site is also unclear. Furthermore, since the 
regulation of peripheral and central OT secretion might be mediated independently of one another 
(70), peripheral measurement may not necessarily reflect central activity.  
A second challenge lies in the confirmation of a diagnosis of OT deficiency, since the physiological 
mechanisms involved in OT regulation are still not fully understood. Akin to the demonstration of 
ACTH or GH deficiency in patients with hypopituitarism, a stimulation test might be required to 
completely unmask OT deficiency (63). The optimal method by which this can be confirmed 
reproducibly needs to be established, whilst studies have already suggested that the presence of 
central diabetes insipidus is not a reliable enough surrogate (63).    
 
Therapeutic challenges 
A number of therapeutic challenges also need to be overcome before OT can be considered as a 
viable treatment option in hypopituitarism. These include its short half-life, optimal mode of 
administration and the safety profile of chronic administration. OT is currently administered as an 
intravenous preparation to induce or augment labour, and used intramuscularly or intravenously in 
the prevention and treatment of postpartum haemorrhage. Neither of these modes of delivery are 
viable as a long-term treatment option, not least because of the very short half-life of OT (11). 
Intranasal OT is an unlicensed but commercially available preparation which in supra-
physiological doses appears to cross the blood-brain barrier (71). This suggests that intranasal OT 
might exert its actions, at least in part, through central as well as peripheral pathways. However, 
the typical dosing frequency of six sprays four times daily (24 IU) is inconvenient. Furthermore, 
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it is unclear whether the observation made in mice of greater efficacy with respect to weight loss 
in response to continuous as opposed to bolus OT delivery (72) carries the same physiological 
importance in humans. Despite these limitations, intranasal OT has been used widely in human 
research studies with largely reassuring safety data to date, at least in the acute setting. In the 
1960s-1970s intranasal OT was used clinically as an alternative to intravenous OT in the induction 
and maintenance of labour. A study of over 1800 women treated in pregnancy showed a low rate 
of adverse events (73). There are fewer safety data with respect to chronic administration, although 
a recent systematic review of adverse events following long-term application (>5 weeks) in 
patients with ASD gave further reassurance (74). The most common adverse events were nasal 
discomfort, tiredeness, irritability, diarrhoea and skin irritation but the frequency of these did not 
differ from placebo. Chronic intranasal OT administration has also been shown to be safe in other 
patient groups (19, 31, 32). Nevertheless, observations from OT use in pregnancy indicate that 
headache and nausea are the most common side-effects that limit tolerability, whilst cardiovascular 
events (arrhythmias, blood pressure fluctuation) and hyponatraemia may cause particular clinical 
concern. These may be mediated in part via off-target actions at AVP receptors. Moreover, the 
actions of OT in down-regulating activity of the hypothalamic-pituitary-adrenal axis (33-36) 
require particular attention when considering OT for use in hypopituitarism.  
Longer-acting OT analogues may circumvent some of these therapeutic challenges, notably with 
respect to extended half-lives leading to reduced frequency of administration. Carbetocin, [Ser4, 
Ile8]-oxytocin and [Asu1,6]-oxytocin are three such examples which have been shown to reduce 
weight and improve glucose regulation in obese diabetic mice (19, 75). However, human data are 
currently lacking.   
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Conclusions 
Whilst a number of studies have suggested that hypopituitarism may be associated with OT 
deficiency, and that OT administration has the potential to improve neuropsychological outcomes, 
a number of challenges remain. A better understanding of the physiological regulation, interplay 
with other endocrine axes and mechanisms of action of OT is critical, as are improvements in 
measurement techniques, in order to understand if hypothalamic disease and hypopituitarism are 
truly associated with OT deficiency or not. Further studies are also needed to confirm an 
association of any deficiency in OT secretion with adverse psychological and metabolic outcomes. 
Interventional studies are subsequently needed to clarify which dose, mode and frequency of OT 
administration is associated with the best clinical outcomes, whilst long-term trials will need to 
demonstrate an acceptable safety profile. Despite these many challenges, recent observations have 
highlighted the OT axis as worthy of further study in patients with craniopharyngioma and 
hypopituitarism, and suggest that OT replacement might have the potential to improve clinical 
outcomes in patients with these conditions.  
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Figure 1. Oxytocin synthesis and secretion 
Figure 2. Actions of oxytocin 
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Table 1. Clinical studies of OT in craniopharyngioma and hypopituitarism. 
Study  Design Participants Measures Oxytocin measurement Key findings 
Daubenbüchel et al (61) Case-control 34 CP patients. 73 
healthy volunteers.  
Baseline and stimulated (post-meal) 
OT concentrations. Associations with 
anthropometric and radiological 
parameters 
Saliva. Enzyme 
immunoassay after 
extraction.  
Reduced OT concentrations in patients 
with anterior hypothalamic surgical 
lesions.  
Change in OT after meal in CP patients 
correlated with BMI.  
Gebert et al (63) Case-control 26 CP patients. 26 
healthy controls  
Baseline and stimulated (post-
exercise) OT concentrations. 
Empathy, depression and anxiety 
scores. 
Saliva. 
Radioimmunoassay after 
extraction. 
Blunted OT release post-exercise in CP.  
Higher baseline OT associated with 
higher trait anxiety.  
Blunted OT release linked with higher 
state anxiety.  
CDI not a reliable surrogate for OT 
deficiency  
Daughters et al (64) Case-control 20 patients with CDI 
and AP. 15 patients 
with AP alone. 20 
healthy controls.   
Baseline OT concentrations.  
Empathy tasks (Reading the mind in 
the eyes; facial emotion recognition). 
Personality measures.  
Saliva. Enzyme 
immunoassay after 
extraction.  
Reduced OT concentrations in AP 
irrespective of CDI.  
Impaired empathic ability in patients with 
AP.   
Hoffmann et al (65) Acute intranasal 
OT 
administration 
10 CP patients.  OT concentrations before and after 
intranasal OT administration.  
Emotion recognition (Geneva 
multimodal emotion portrayals 
corpus; Multidimensional mood 
questionnaire) 
Saliva and urine. 
Radioimmunoassay after 
extraction.  
Improved emotion identification in 
patients with post-surgical lesions in the 
anterior hypothalamus.  
Cook et al (60) Case report Child with CP Parent-observed behaviour in 
response to intranasal OT.   
Not measured Increased desire for socialisation. 
Improved affection towards family. 
Hsu et al (66) Case report Boy with CP BMI and parent-observed behaviour 
with respect to food intake in 
response to chronic intranasal OT 
alone or in combination with 
naltrexone.   
Not measured Reduction in weight and BMI z-score.  
Improved satiety, reduced urgency to eat 
and decreased food preoccupation. 
CP Craniopharyngioma. CDI Central diabetes insipidus. AP Anterior hypopituitarism. BMI Body mass index. 


